This article describes the results ofotoaco ustic emissions testing in five patients with sensorineura l hearin g loss. We conducted an audiologic evaluation and perform ed image and cere bralfun ction studies on each patient. Our investigation revealed that all fi ve had spontaneo us otoa cou stic emi ss io ns and/or di st ortion p rodu ct otoacoustic emissions. Pharmacologic treatm ent with anxiotvtics, antidepressants, and anti convulsant dru gs was succes sf ul in alleviatin g symptoms in three patients. An organic and a central fun ctional cause of symptoms was fo und in the remai ning tlVOpatients. Bef ore pharmacologic therapy, the spontaneo us otoaco ustic emissions were of high intensity, and the distortion p roduct emissions were minimal. Following dru g therapy, the fo rme r disapp eared and the latter appe ared.
Introduction
Kemp ' s des cription of otoacoustic emi ssions in 1978 spurred great intere st in cochlear micromechanic s and the modulation mechani sms invol ved in the transmission of auditory information.' Since then , many investig ation s have shown that otoacoustic emissions are the result of the rapid contraction of the outer hair cells.>' With their interconnected endoplasmic reticular structure and the pres ence of numerou s contractil e proteins (e .g ., nonpolymerized actin , alpha-active myosin, fibrin , and tubulin) , these cell s have the capacity to move the tectorial and basil ar membranes to a frequency of 30 kHz . Different stimuli, both internal and external, are capable of producing a depol arization and contraction of the outer hair cells. The y includ e dire ct electrical stimuli, mechanical stimuli brought about by the deflection of cilia, and chemical stimuli produ ced by iontophoresis with acetylcholine, a neurotransmitter present in the cochlear efferent path way.
Schuknecht' and Warr and Guinan" describ ed the presence of a large number of neuron s in the auditory cort ex that extend par allel to the cochlear afferent pathw ay. The se neuron s are conn ected to the lowe st hearing centers and the organ of Corti. Years ago, Rasmussen described the presence of 300 to 600 nerve fibers that extend from the upper olivary complex, through the anastomoti c branch of Oort , to the lower vestibular nerve, and down to the inner and prim aril y the outer hair cells. ' The fibers that originate in the lateral area of the upper olivary complex extend through the ipsilateral cochlea and end under the ner ve fibers on the inner hair cells. Th e fiber s that originate in the median area of the upper olivary complex extend throu gh the contralateral cochlea down to the outer hair cells .
According to Spoendlin, three or four fibers end on each outer hair cell , but none ends directly on the inner hair cells." Lim wrot e that cochlear afferent pathw ay acti vity can be adju sted by efferent impul ses through the subsynaptic cistern s of the inner hair cells.' His findin gs are consistent with the experience of other authors, who have observed a decrease or disappe aranc e of otoacoustic emissions following the application of contralateral auditory stimulation in hum ans and other mammals." !'
In this article, we describe the results of our study offive patient s with sensorineural hearing loss who underwent otoacoustic em ission s testing. Our findings lead us to believe that different disorders of the mechanisms of auditory regulation and modul ation might be directly responsible for hearing loss, tinnitus, and vertigo ofretrocochlear origin. We belie ve that these disorders might be studied or diagnosed with the use of otoacoustic emi ssions.
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Rash hasoccurredinapproximately1%ofpatientsrecei vingondansetron. eurol 0UJ.c~/ :Th ere havebeenrare reportsconsistent with,but not di agnosticof, extrapyramidal reactions in patients recer vlng ZOFRAN Inj ect ion, and rare cases of grand mal seizure. Therelati onship to ZOFRAN was uncl ear .
Other: Rare cases of hypokalemiahavebeen reported. Therelat ionship to ZOFRANInjection was unclear . Postoperative Nausea andVomiting (PONV): The10Howingadverse eventshavebeen reported in patients receiving rT)ultlpleeoncorn ttant peri operati veandpostopera tivemedications. Rat esof these eventswerenot si gnificantly different Intheondansetron and pl acebogroups. We recorded the spontaneous otoaco ustic emissions (SOAE) and distortion product otoacoustic emi ssions (DPOAE) of each patient. Patients were considere d to have SOAE when their emiss ion levels were 3 dB of sound pressure level (SPL) higherthan the average level of environmental noise. We classified SOAE into four categories : light (3 to 5 dB SPL), moderate (6 to 10), intense (II to 15) , and very intense (~16 ) . To register DPOAE, we used two pure tones (F l AND F2) of 65 and 75 dB SPL as a stimulu s. Tests were performed sequentially at 0.5 to 8 kHz. The DPOAE following 2FI-F2 are graphica ll y displayed as "distortion product-gram" (DPgram). We use the same four classification categorie s for the DPOAE result s. Case 1. A previously healthy 25-year-old woman complained of a sudden hearin g loss in her left ear, which was accompanied by continuous and intense white-noise tinnitus. She had visited a number of otolaryngologists and had been prescribed various treatment s (e.g ., corticosteroids, vitamin s, and vaso dilators) . When there was no improvement in her condition, she was diagno sed as having apparent viral damage. The woman was described as a perfectionist, and she was very nervous and tense. Prior to her hearing loss, she had gone through a period of family problem s that had put a strain on her state of mind.
Our examination revealed a sensorineural hearing loss in both the hi gh and low freque nc ies. Pneumocisternography and computed tomo graphy (CT) of the cerebellopontine angle ruled out the presence of a neuroma. Otoacoustic emissions testing revealed that an SOAE was present in both ears (figure 1). The SOAE was inten se in the right ear ( 12 dB SPL ) and intense in the left ( 15 dB SPL ). DPOAE was abse nt in the left ear and intense at I to 2 kHz in the right. She was prescribed the benzodiazepine brom azepam ( 1.5 mg q 12h po) and fixedcombination (12.5/5 mg) amitriptyline/chlordiazepoxide (once daily po) for 4 months.
At the conclusion of her drug regimen, we performed another emis sions test (figure 2). Repeat testing showed a significa nt attenuati on of SOAE in the left ear (3 to 4 dB SPL) and a complet e resolut ion in the right. A moderate DPO AE was observed in the left ear (6 dB SPL at 1.5 to 4 kHz), and the DPO AE in the right had incre ased. Audiometry results remained norm al in the right ear , the tinnitu s in the left had disappeared, and hearing loss completely resolved.
. Case 2. A 48-year-old man experienced rotatory dizziness and imbalan ce that became worse with head movement and was associated with tinnitu s in the left ear. Audiometry revealed a slight bilateral and symmetrical sensorineural hearing loss in the high and low frequen -Volume 79, Number 6 cies, with good discrimination. Other hearing test results were normal.
Emissions testing detected a very intense (22 dB SPL) SOAE in both ears and a moderate DPO AE at 4 and 8 kHz. The man was prescribed a treatment regime n similar to that give n to patient I . One month later, repeat testing showed a significant reduction in the SOAE (10 dB SPL ) in both ears and no change in DPO AE in either ear.
Case 3. For several month s, a 49-year-old man had experienced rotatory dizziness, imbalance , nausea, and vomiting, which were follo wed by a hearin g loss and a sensation of pressure in the left ear. These episodes lasted approximately 1 hour and they tended to abate following a long period of sleep. The patient said that the onset of his symptoms coincided with a period of intense stress at work.
Audiometry showed a sensorineural hearing loss in the left ear at the medium frequencies (0.5 kHz to 50 dB and I kHz to 35 dB) and normal hearing in the right. He had good discrimination , good timin g on the auditory brain (evok ed) response (ABR) test, and a normal glycerol test. Magnetic resonance imaging (MRI) was performed on the brain and the posterior fossa, and results were norm al. The otoacoustic emissions study showed a very inten se SOAE in both ears (16 dB SPL); the patient also had a DPOAE in both ears to a level of 2 to 4 kHz, but it was virtu ally absent in the other frequencies. A computerized analysis of electroencephalographic brain mapping showed an irritative epileptiform focus in the left temporal subcortical area. The man was prescrib ed bromaz epam ( 1.5 mg q 12h po) and the anticon vulsant carbamazepine (200 mg ql 2h po).
After 1 week of drug treatment, the patient had begun to experience an allevi ation of the dizziness and an improvement in hearing. After 5 month s of therapy, repeat testing revealed that the patient' s hearing was normal and that the SOAE in both ears had disappeared. His DPOAE had increased and was present in both the high and low frequ encies.
Case 4. A 4-year-old boy had an untreat ed right temporop arietal hematoma of perin atal orig in, which cau sed insomnia and frequent agitation. He had been brought to the clinic for evaluation of a long-evolving deep bilateral hearing loss.
Audiometry showed a deep sensorineural hearing loss, descend ing from 55 dB at 128 Hz to 110 dB at 4 kHz in the right ear and showing profound deafness in the left. Impedance test results were normal, and the ABR test showed a good response only in the right ear at 80 dB. Otoacou stic emissions testing showe d an intense SOAE in both ears (10 to 12 dB SPL) and a moderate DPOAE, especially in the high frequenci es. Electroencephalographic brain mapping showed the presence of focal epileptiform irritative activity in the right central regions of the frontal lobe. 
Figure I . Case I : Initial otoacoustic emissions testing revealed that SOAE was intense in the left ear (A) and intense in the right (B). DPOAE was absent in the left ear (C) and intense in the right (D).
Case 5. Four months before coming to our clinic, a 62year-o ld woman had suddenly experienced a sensation that both of her ears were full. This feeling had been accompanied by left tinnitus , rotatory dizz iness , imbalance, and vomi ting, which worsened with head movement. The following day, she said her right ear had returned to normal , but the tinnitus and hearing loss in the left had persisted. An otolaryngologist had prescribed different treatments, but her condition did not improve.
The ENT physical examination was normal. Audiometry revealed a severe sensorineural hearing loss in the left ear . The woman's ABR conduction time was normal, but her otoacoustic emissions analysis detected a very intense SOAE and DPOAE in the right ear, and an intense SOAE and no DPOAE in the left.
CT of the brain detected a lacunar infarct on the right 442 side of the glob us pallidus and the putamen of the right hemisphere.
Discussion SOAE was found in the absence of DPOAE in patien ts 1, 2, and 3. In these three cases , drug therapy was prescribed, and these patients experienced a definite improvement, as their tinnitus, dizziness, and vertigo disappeared . Moreover, patient 3 also experienced an improvement in hearing. Repeat testing revealed how effective drug treatment was in modifying otoacoustic emis sions , and we observed a reduction or resolution of SOAE and an increase in DPOAE.
In cases 4 and 5, SOAE and DPOAE were found in apparently cofotic ("de ad") ears and in ears with severe hearing loss. CT and MRI allowed us to identify an organic and a central functiona l cause in patients 4 and 5, respectively. Most investigators believe that otoacousticemissionswhether they be spon taneo us, product distortion, or evoked-are present in healthy cochleae.P-" Otoacoustic emissions testing is regarded as the only test capab le of demonstrating the function of the organ of Corti, especially in the outer hair cells, in an objective, noninvasive, and reproducible way. There is also a consen sus that differen t noxious factors that can affect the cochleasuch as ototoxics (acetylsalicylic acid, aminoglycosides, etc.) and aco ustic disorder s-diminish or eliminate otoacoustic emissions.": " Finally, it is accepted that otoacous tic emissions are modified by stimu lation of the effere nt auditory system, as contralateral acoustic stimuli reduce distortion product and evoke d emissions.17·20 For these reasons, the use of otoaco ustic emiss ions testing is widely acknowledged as useful for making auditory assessments of newborns and patients who have been exposed to ototoxics or environmental noise, and for controlling cortipathy-that is, damage to or a lesion in the organ of Corti.
In the five patients we studied, the diagnosis was not clear, although in some of them, the possibility of endolymphatic hydrops, sudden hearing loss, etc., was proposed. However, the presence of otoaco ustic emissions in these patient s was a sign that the orga n of Corti was undamaged, and this suggested the possibility that symptoms originated from a retrocochlear or centra l origin.
In our study, our attention was drawn to the relationship between SOA E and DPOAE in patients 1, 2, and 3 and the resolution of symptoms following a course of pharmaco- 
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(oI/O%8CiIJ oksol uPol l )i J i [ {j )L1f 1~D. RIED, RIED, AVILES logic treatment. There is no description in the literature of any correlation betwe en these types of otoacoustic emi ssions in patients who experien ce sensorineural hearin g loss, tinnitu s, or vertigo, but there are some reports of otoacou stic em issions in patients who had sensorineural hearing IO SS. 21.25 The presence of otoacoustic emission s in patients 4 and 5, especially SOAE , led us to con sider intense irrit ative activity and a lacunar infarct, respectively, as possible explanations for these patients' symptoms. Based on the finding s of our study, we pose a serie s of hypothe ses:
• The presence of otoacoustic emissions, either SOAE or DPOAE, implie s that the cochlea and outer hair cells are functionall y normal.
• The presence of intense SOAE should be a common findin g in patients who have an undamaged cochlear system but who have some retrocochlear or centr al disorder that impedes the normal inhibitory activity of the efferent auditory system.
• The pre sence ofDPOAE in an ear with a sensorineural hearing loss is a sign that the patient has a healthy cochl ea and normally functioning outer hair cells and efferent auditory system. Therefore, the problem probably has a central origin .
• Amon g the causes that might expl ain some organic pathologies are lacunar infarcts, sclerosis, brain lesions, and arteriovenous malformations.
• Among the etiologies of functional disorders are electrical cau ses, factor s similar to those that cause epilepsy, depression, and stress, all of which have been propo sed by other author s.P -"
• The use of antiepileptic, anxiolytic, and antidepressant drugs in some patients with audiovestibular disorders who are studied with otoacoustic emissions testing has led to a clinic al improvement in many of them . Otoacou stic emis sions testing helps us establish a diagnosi s and allows us to monitor the effect of treatment.
To summarize, SOAE and DPO AE testing of patients who have a sensorineural hearing loss allows us to objectively evaluate the functional state of the organ of Corti and the efferent cochle ar pathway. The presence of an intense SOAE and the absence of a DPOAE suggests a retroc ochl ear disorder of the efferent pathw ay from the brain , which in some cases can be rever sed with drug therapy. The presence of DPOAE in an ear of a patient with a hearing loss indicates a possible brain failure. Along with audit ory evoked potent ials, MRI , and brain function studies, the study of otoacou stic emissions allows us to examine lesions of retro cochlear or central origin and of different etiologies (i.e., organic or functional ). Otoacou stic testing sheds light upon a field of unknown dimensions in the diagnosis of central auditory pathology, and it can suggest a possible central or efferent origin to some balance disord ers.
